StockGuide AI
Aktien verfolgen
EN RU ES DE
Ligand Pharmaceuticals

Ligand Pharmaceuticals

Preis: 254.57

Unternehmen und Geschäftsmodell

Ligand Pharmaceuticals is a biotechnology company focused on developing and commercializing technologies that enhance drug discovery and development. Its core products include a range of proprietary technologies and partnered programs that facilitate the creation of therapeutics across various disease areas. Major business segments include royalty revenue from partnered products and licensing agreements. The primary revenue sources stem from collaborations with pharmaceutical companies and royalties from sales of drugs utilizing Ligand's technologies.

Anlageprofil

The investment profile of Ligand Pharmaceuticals is more aligned with value investors, given its current market position and revenue trends. The stock may appeal to those seeking potential long-term appreciation, although recent performance indicates challenges. Investors should consider the company's volatility and risk factors when evaluating their investment horizon.

Offizielle Website

Fundamentale Kennzahlen (experimentell)

EPS (TTM) — Gewinn pro Aktie der letzten 12 Monate, $
7.84 OK
Umsatz QoQ — Umsatzwachstum im Quartalsvergleich
-13.3% ↓
EPS-Überraschung
-11.4% schlechter als erwartet
20d Volatilität
1.8% stabil
FMP / FinFeed-Daten aktualisiert: 2026-06-11
Empf.: Halten Potenzial: 65 Risiko: 62 Aktualisiert: 2026-06-11 05:38
Wie die Empfehlung funktioniert
Warum KI so denkt:
Strong price momentum, but declining revenue raises concerns.

Im Portfolio verfolgen

Preischart

KI-Empfehlung Analystenprognose Kalenderereignis Positives Signal Negatives Signal Neutral / Update Halten / informativ B My buy S My sell
Änderungen der AI-Empfehlung
Datum Vorher Nachher Grund
2026-05-24 02:44 Verkaufen Halten Weak fundamentals and high risk limit upside potential.
2026-05-16 02:46 Halten Verkaufen Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:20 — Halten Weak fundamentals and negative momentum raise concerns.
Analystenprognosen
Datum Analyst Action Ziel Preis damals
2026-04-30 10:09 H.C. Wainwright Ziel erhöht 243 → 289 224.86
2026-04-28 11:36 RBC Capital Ziel erhöht 235 → 252 241.79
2026-04-27 18:05 Stifel Nicolaus Ziel erhöht 230 → 255 241.79